Klotz U, Ogbuokiri J E, Okonkwo P O
Dr. Margarete-Fischer-Bosch Institut für Klinische Pharmakologie, Stuttgart, FRG.
Eur J Clin Pharmacol. 1990;39(6):607-8. doi: 10.1007/BF00316107.
Human pharmacokinetic data on the new anti-parasitic agent, ivermectin, are scanty. For the evaluation of its disposition a specific HPLC assay with sensitive fluorescence detection was developed. Applying equilibrium dialysis, plasma protein binding of ivermectin was measured in five healthy individuals and it averaged 93.2 +/- 4.4% (SD). Such strong binding should be taken into consideration, especially in patients with malnutrition or with diseases in which a decrease in plasma proteins and consequently a higher free fraction of ivermectin could be expected.
关于新型抗寄生虫药物伊维菌素的人体药代动力学数据较少。为评估其处置情况，开发了一种具有灵敏荧光检测的特定高效液相色谱法。应用平衡透析法，在五名健康个体中测量了伊维菌素的血浆蛋白结合率，其平均值为93.2±4.4%（标准差）。应考虑到这种强结合情况，尤其是在营养不良患者或患有血浆蛋白减少从而预期伊维菌素游离部分会增加的疾病的患者中。
